EuroBiotech: More Articles of Note

> The FDA cleared Transgene to start a phase 1 trial of its personalized immunotherapy TG4050 in ovarian cancer patients. NEC is co-financing the cancer vaccine trial. Release

> UniQure posted updated data on its hemophilia B gene therapy. The data show the high Factor IX activity seen early in the study has been sustained up to six months. Statement

> A phase 2 trial of Modus Therapeutics’ sickle cell disease drug failed to show a meaningful benefit. The setback led Modus to weigh its options for further development of the asset. Release  

> TreeFrog Therapeutics raised €7 million ($7.8 million). The French startup aims to move one of its cell therapy research programs into humans in 2024. Statement 

> Pfizer nominated a preclinical development candidate under its collaboration with Sosei Heptares, triggering a $3 million milestone payment. The partners are yet to disclose the target of the small molecule. Release  

> Ixaltis completed phase 2 development of its urinary incontinence drug, litoxetine, setting the French biotech up to move into phase 3. Statement